SIGRID Therapeutics announces the U.S. launch of Carb Fence™, its flagship medical food powered by patented SiPore® technology. The launch brings the clinically evaluated 9 g daily SiPore® dose to market for the first time, marking a major commercialization milestone following more than 15 years of research and multiple clinical studies.
Sigrid Therapeutics (Sigrid), a science-driven consumer health company developing innovative solutions for metabolic health, today announced the appointment of Claus Kjaersgaard as its new Chief Executive Officer. Claus will assume the role on 1 February 2026.
Sigrid today announced that it has entered into an exclusive global licensing and research collaboration with a leading multinational consumer health company to expand the SiPore® technology platform into consumer oral health through a partner-led approach.
After an exceptionally successful online launch earlier this year, Sigrid Therapeutics and Kronans Apotek are now ready to take the next step: SIGRID Stabiliser will be launched on store shelves across the country in the fall of 2025.
Sigrid Therapeutics AB (Sigrid) announces that CEO Sana Alajmovic will leave her operational role on January 31, 2026 to take up a new position outside of Sigrid's operations and that does not compete with the company.
SIGRID, the Swedish innovative consumer health company behind the patented SiPore® technology, today reports new clinical and commercial milestones for its innovative dietary supplement Glucose Stabiliser.
Sigrid Therapeutics announces today that their innovative product, Sigrid Stabiliser, which was previously only available through the company's own e-commerce, will now be launched and offered exclusively at Kronans Apotek starting in February 2025.
Sigrid Therapeutics today announced the signing of a strategic partnership with GetHealthy.store, a leading US provider of e-commerce solutions for healthcare providers selling healthcare and nutritional products.
Sigrid Therapeutics announced today that recruitment to the SHINE clinical trial, which is evaluating the company's breakthrough product SiPore21® for long-term diabetes control, has been completed.
Sigrid Therapeutics announced today that the company has recruited over 50% of patients in SHINE, a clinical trial evaluating SiPore21® for the treatment of elevated glucose levels.
Sigrid Therapeutics today announced that the company has launched Glucose Stabiliser in the US.
Sigrid Therapeutics has secured SEK 44 million in a successful and oversubscribed financing round, underscoring the strong confidence of investors in Sigrid's innovative SiPore technology®.
Sigrid Therapeutics is pleased to announce the start of the SHINE clinical trial for SiPore21® – an innovative medical device designed for long-term maintenance of blood sugar and weight control.
Sigrid Therapeutics (Sigrid), a Swedish consumer healthcare company, announced today that Professor Iain Chapple, a world-leading expert in oral health from the University of Birmingham's College of Medical and Dental Sciences, has been appointed as the company's scientific advisor.
Sigrid Therapeutics, a Swedish consumer-focused technology company in consumer health, announced today that an additional SEK 10.6 million has been added to the company to accelerate the commercialization of its portfolio of dietary supplements based on SiPore®.
Sigrid Therapeutics, a Swedish consumer healthcare technology company, today announced that it has appointed Mattias Ankerberg as Chairman of the Board.
Sigrid Therapeutics, an innovative, consumer-focused health company that has developed a new technology, SiPore ® against prediabetes and obesity, announces today that the company, after 10 years of research, is in the starting blocks to launch its new, clinically proven product SiPore21 ® .
Swedish healthtech startup Sigrid Therapeutics is on its way to preventing two of the world's biggest health challenges, type 2 diabetes and obesity, with its SiPore15® powder.
Sigrid Therapeutics, a technology company specializing in the prevention of type 2 diabetes and obesity, announced today that the company has been granted a patent by the United States Patent and Trademark Office (USPTO).
Sigrid Therapeutics (Sigrid) announced today that the results from the company’s STAR study have been selected for presentation at the American Diabetes Association’s 80th Scientific Sessions, June 12-16, 2020.